[Signal Transduction and Targeted Therapy] Investigators showed that the oncogenic BCR-ABL1 of chronic myelogenous leukemia and the cellular ABL1 tyrosine kinases phosphorylated and inactivated Smad4 to block antiproliferative TGF-β signaling.

[Science of The Total Environment] RNA interference was performed to understand the function of astakine in hematopoiesis and apoptosis in Litopenaeus vannamei under ammonia-N exposure.

[Cell Reports] The authors integrated extensive longitudinal functional assessments of HSC-specific lineage tracing with single-cell transcriptome and epitope profiling.

[Cell Reports] Scientists found no differences in HSC function and hematopoiesis in latexin (Lxn) knockout male mice under physiologic and myelosuppressive conditions. They also found that thrombospondin 1, a downstream target gene of Lxn in female HSCs, was repressed in male HSCs.

[Blood Cancer Journal] To pinpoint mechanisms facilitating the transformation of ABL1-deficient cells, Abl1 was knocked down in 32Dcl3-Abl1ko cells by CRISPR/Cas9 followed by the challenge of growth factor withdrawal.

[EMBO Reports] Researchers demonstrated that the potential of murine and human HSCs was maintained when cultivated for 2 days ex vivo at a pH of 6.9, in contrast to cultivation at the commonly used pH of 7.4.

[Cellular Oncology] An Atp8a1 knockout mouse model was employed, from which the long-term and short-term HSC population was analyzed to assess their abundance and function.

[iScience] Investigators demonstrated that the sinusoidal endothelium was an essential and conserved niche component in the zebrafish kidney. Histological analysis revealed that runx1:mCherry+ hematopoietic cells were predominantly detected in the dorsolateral region of the kidney.

[Molecular Therapy-Methods & Clinical Development] Considering the impact of anti-Ad5/HDAd5/35++ neutralizing serum antibodies present in the human population, researchers generated HSC-retargeted HDAd6/35++ vectors derived from serotype 6.

[Leukemia] Scientists reported updated results of a Phase I, open-label, nonrandomized trial, NCT02081378, assessing the safety, tolerability, and antileukemic activity of asciminib monotherapy 10–200 mg once or twice daily in 115 patients with chromosome–positive chronic-phase chronic myeloid leukemia without T315I .

[Journal of Hematology & Oncology] The authors discuss recent updates in the classification and risk stratification of AML, explore the literature regarding low-intensity and novel oral combination therapies, and briefly highlight investigative agents currently in early clinical development for high-risk disease subtypes.

[Stem Cell Reviews and Reports] Recent findings have identified novel progenitor subsets of bone marrow adipocytes recruited during the bone marrow adipogenesis within different skeletal and HSC niches.